Market Scenario 

Global hemostats market was valued at US$ 2,744.28 million in 2023 and is projected to hit the market valuation of US$ 4,568.90 million by 2032 at a CAGR of 8.7% during the forecast period 2024–2032.

The increase in the number of surgeries conducted worldwide is the main driver for hemostats market and related surgical instruments. Hemostats are increasingly being used with each as the number of people suffering from chronic illness is increasing. This is especially true for aging population as they are more likely to have these diseases and often required some form of surgeries.  According to the World Health Organization, there will be 1.4 billion people aged 60 years and above by 2030. This represents a growth from 1 billion in 2020, which also accounts for about 16% of total global populations as estimated by WHO. These statistics imply that more operations will be required because an aging population requires many interventions related to their health problems associated with age like those caused by chronic illnesses including diabetes mellitus type II (DMII) among others.

In this context, it is worth mentioning that chronic diseases such as cardiovascular disorders, cancer, and obesity contribute greatly towards driving up demands for surgical procedures too as they are responsible for approximately 71% deaths globally, according to WHO report on noncommunicable diseases. Moreover; as per WHO data published last year showed that over 35 million people die each year around world from heart attacks or strokes alone making them leading cause death worldwide followed closely by HIV/AIDS-related complications which claim lives numbering close two million annually.

Furthermore, technological advances together with latest trends within hemostatic products have been identified as important factors behind hemostats market growth. Technological breakthroughs like introduction topical agents among others offer improved safety efficacy convenience thus driving their usage not only during open but also minimally invasive surgeries where demand tends vary depending various regions across globe. North America, especially the US & Canada, dominate market share due advanced healthcare infrastructure, high expenditure levels coupled large number of cosmetic surgeries performed each year representing about 40% share overall hemostats market. According American Society Plastic Surgeons’ annual survey, over 1.5 million cosmetic surgery procedures were done in the US alone in 2023.

To Get more Insights,  Request A Free Sample 

Market Dynamics

Driver: Rising Demand due to Chronic Disorders

The growing prevalence of chronic diseases worldwide continues to be a key driver for the hemostats market. The increase in these conditions globally has led to an increased need for surgical treatments which prompts the demand for effective hemostatic products. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are still the leading cause of death globally with about 17.9 million deaths per year. This number is projected to rise and it is estimated that there will be around 23.6 million deaths by 2030 due to such illnesses. Additionally, cancer incidence rates are also increasing; therefore, International Agency for Research on Cancer predicts that there will be approximately 18.1 million new cancer cases diagnosed worldwide in 2024 and this number is expected to grow up to 24 million by 2035. Moreover, Lancet Global Health stated that surgical conditions account for almost 37% of global disease burden including injuries and musculoskeletal disorders.

Another important factor contributing towards higher demand for hemostatic products is ageing population, which witnesses growth in age related chronic disease. Thus, it is making them more prone towards developing various types of chronic ailments like heart attack or stroke. According to United Nations projections by 2050, 1 out of 6 persons worldwide will have crossed 65 years old threshold thereby creating additional need for products in the hemostats market.  Moreover, recent data published by International Diabetes Federation, there could be as many as 783 million diabetics people by 2045.  In addition to this, the World Obesity Federation warns about growing numbers of overweight people with projections showing 2.3 billion obese children and adults worldwide in 2024 alone. These conditions usually require some form surgery thus driving up demand for hemostats. Also, WHO data indicate that more than 550 million people suffer from respiratory diseases like asthma or chronic obstructive pulmonary disease (COPD) globally. Kidney International Supplements revealed 850 million affected by kidney problems around the world in 2023. 

Challenge: High Cost of Advanced Technologies

The global hemostats market is currently faced with the challenge of high prices of advanced hemostatic technologies and products. This, in turn, restricts patients’ reach to these lifesaving remedies, besides affecting market expansion in areas where cost is an issue. This problem is universal. Globally, about 1.2 billion people lack access to basic surgical care, according to World Journal of Surgery 2023 and the main obstacle towards achieving it is lack of funds. Such limitation disproportionately affects less developed countries where payment for operation can lead into financial catastrophe for any family living below poverty line. For instance, average price for one surgery performed within United States was $1,601 as per PLOS One 2022. However, several other procedures especially those requiring sophisticated technologies could cost much higher than that. For example, A study published in Journal of Cardiothoracic Surgery shows that usage of advanced hemostatic agents during heart operations added $2,350 on average to total medical bill.

In addition, there are also considerable extra expenses associated with every patient treated in the hemostats market - mentioned by various sources such as Journal of Cardiothoracic Surgery (2022), which indicated an increase in costs by $2,350 when these were employed during cardiovascular surgeries. It has also been found that some may even go up to US$ 500 each unit while talking about certain types or brands; Kaiser Family Foundation survey 2022 says that 42% Americans do not seek health care due to high charges.

This problem mainly affects low-income countries where availability essential surgical items like hemostats remains limited according British Journal of Surgery. It is found that only 38% percent hospitals situated in these parts have continuous access necessary supplies required for operation. Additionally, costlier advanced products may not be adopted widely compared to cheaper traditional ones like suture materials and ligatures particularly within structures sensitive towards expenditure as indicated by Journal of Healthcare.

Trend: Increased Use of Biodegradable Hemostats

Driven by the need for sustainable and patient-friendly solutions, biodegradable products are becoming more prevalent within the hemostats market. This growth is driven by a predicted 22% rise in surgical procedures over the next ten years; traditional agents must often be removed or pose long-term hazards whereas their biodegradable counterparts can be absorbed into the body thus reducing follow-up surgeries and complications. This trend is supported by several innovative products such as Surgicel which is an oxidized regenerated cellulose (ORC) that reduces post-operative bleeding complications by up to 85%. Hemopatch on the other hand is collagen-based resorbable hemostat that promotes rapid clotting and gets absorbed within eight weeks, showing 90% efficacy rates during clinical trials. Moreover, Floseal - gelatin combined with thrombin achieving hemostasis within two minutes for 93% cases, Tachosil being fibrin sealant patch being absorbed within six months lowering hospital stays by 15%. Arista AH is a plant-based absorbable hemostatic agent in the global hemostats market that has been shown to have absorption rate of about 30% faster than traditional agents.

In 2022, the US FDA approved 15 new biodegradable hemostatic products, reflecting a growing confidence in their safety and efficacy. Additionally, hospitals adopting these products have reported a 25% decrease in surgical waste. With healthcare systems increasingly prioritizing sustainability, the demand for biodegradable hemostats is expected to continue its upward trajectory. 

Segmental Analysis 

By Type

Based on type, the topical hemostats are dominating the global hemostats market due to their wide range of application in different surgical disciplines and their quickness in achieving hemostasis. In 2023, the topical segment generated over 85.46% market share, which translates to worth $2,345 million and is projected to keep growing at the highest CAGR of approximately 6.09%. This boom can be attributed to many things chief among them being the rise in the number of surgeries performed worldwide. It is estimated that there were 1.5 million cardiac operations done around the world in 2023, which necessitated effective control over bleeding sites. What sets topical hemostatic apart from other products used during such procedures is that they act locally and directly on wounds thereby limiting blood flow outwards or downwards.

There is also an increase in the need for these medications due to higher numbers of less invasive procedures carried out through keyhole incisions or endoscopic entry points. In America alone, between 2020 and 2022, there was an 18% surge in MIISs (minimally invasive surgeries). Another reason why more people are opting for them has to do with patients’ preference towards quicker recoveries and lesser scarring. They help speed up healing processes while at the same time cutting down on postoperative complications related to bleeding thus making it possible even in cases where operation time would have been longer than usual otherwise.

By Formulation

Based on formulation, the global hemostats market is lead by matrices and gels formulation. In 2023, the segment held over 34.24% market share. In the same year, approximately 35% of all hemostatic sales were generated by matrixes and gel products. This dominance is driven by their ease of use, biocompatibility with human tissues as well as cost effectiveness in comparison with other types such as sponges or powders which can be expensive over time due their high consumption rates during surgeries. Furthermore, they can easily adhere onto uneven surfaces or inside cavities left after an operation – making them very versatile indeed. For example, during cardiac surgeries where accuracy counts most- matrixes + gel type performs 90% faster than any other method known so far. Similarly, its ability not only to adapt but also conform within complicated anatomical structures without causing injury among patients remains unmatched.

Additionally, with the aging population, people are likely to undergo multiple surgeries and often faced with complications that are requiring efficient solutions like those provided by matrices and gels formulation. The year 2023 alone recorded a 15% growth in the number of surgeries performed in people above 65 years old. This is further indicating need for reliable fast acting homeostat. On top of this, minimally invasive surgery 18 times higher than 2020. According recent projections, over 80% hospitals still prefer using Matrix & Gel based products.

By Application 

Based on application, the orthopedic surgery segment is dominating the global hemostats market with revenue share of over 30.74% as they require more hemostats than any other type of surgery. Operations on bones, such as joint replacement or spinal surgeries to fix fractures, often involve a lot of manipulation of bone and soft tissues, may results in significant bleeding. For instance, an AAOS study revealed that only in the US approximately 1.5 million hip and knee replacements are performed per year with an expected increase of 70% by 2030. This vast number inherently necessitates effective hemostatic agents for controlling hemorrhage during operation; thus, ensuring patients’ safety too. Such interventions like spinal fusion or correctional treatment for severe fractures need careful attention paid towards stopping bleedings because large vessels might get damaged and lead to substantial blood loss.

According to the Global Spine Journal of 2023, spinal surgeries comprise almost a 25% of all major orthopedic procedures and frequently demonstrate higher intraoperative bleeding compared with other types of operations. Therefore, necessitating advanced hemostatic agents’ usage for decreasing complications rates and enhancing surgical results in the hemostats market. Additionally, these products have found more application in orthopedic surgery due to advancements made in hemostasis technologies over time. For instance, next generation fibrin sealants or thrombin-based items among others.  This dominance of orthopedic surgeries is also attributed to increased preference towards less invasive methods coupled with need for quick effective hemostasis that will accelerate healing process. The study further reveals that up to 30% reduction may be achieved in transfusion rates if these drugs were integrated into surgical protocols – according Journal of Orthopedic Research.

By End Users

Based on end users, the hospitals are the most common consumers in the global hemostats market with over 56.20% market share thanks to a large number of surgeries are conducted within their premises. Hemostatic agents are vital in controlling bleeding during surgeries and are needed to perform various major and minor operations every day. In 2023, 70% of all surgeries were performed in hospitals while Ambulatory Surgical Centers (ASCs) accounted for only 20% and home care settings made up just 10%, according to the U.S. National Library of Medicine. Also, because they generally have more money available than other types of medical facilities, hospitals can purchase state-of-the-art hemostasis technologies that will provide their patients with the best possible treatment. They have specialized teams who can do different kinds of operations like cardiac surgery or neurosurgery which use many different types of these products too; for example, in 2023 alone cardiac surgeries caused nearly one fifth (20%) of total usage rate by themselves. For another thing, regulatory bodies often require high-quality agents be available throughout hospitalization so as to meet safety standards while still achieving good health outcomes.

According to the American Hospital Association (AHA), there were 38.5 million hospital admissions in the U.S. in 2023 with over 48 million surgeries being performed, out of which about 15% were procedures where extensive blood loss was anticipated. Additionally, as per Global Hemostats Market Report 2023; hospitals account for 56.20% share in the overall consumption volume worldwide. Furthermore, equipped with robust surgical infrastructure and ability to handle severe trauma cases as well emergency procedures characterized by massive blood loss that require quick control measures. 

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis

With the US, Canada and Mexico being part of it, North America is the largest consumer and manufacturer in the global hemostats market globally with a revenue share of more than 40.74%. This dominance is due to excellent healthcare systems and many surgical operations. In the US alone, around 40-50 million major surgeries are performed each year. The medical device industry in the USA is strong; therefore, huge amounts are invested into R&D which leads to innovations in hemostatic products. Another important factor is the expenditure on health care in this region: $4.8 trillion were spent by US only throughout 2023 (around US$13,493 per person). Such large investments support demand for advanced surgical items like these ones. Demand is also fueled by chronic diseases such as heart conditions — over 240,000 coronary artery bypass graft (CABG) surgeries take place annually here; moreover, ageing population that needs more interventions plays its role too.

Europe is the second largest consumer and manufacturer of hemostats market. A strong healthcare infrastructure, a high number of surgical procedures and an aging population are kinds of demand in the area. There is between 1,000 and 6,000 surgical procedures per 100,000 people in Europe; Germany and the United Kingdom have higher rates than other countries do. Surgical interventions become necessary as more than one fourth (25%) of the European Union’s citizens are over 60 years old. Among healthcare systems established within such countries like France or Germany where amount spent on health care services reaches significant levels, there also lies this support for advanced hemostatic solutions adoption. For example, it can be ensured through such restrictive frameworks as MDR (European Medical Device Regulation) which should trigger safety measures while producing medical devices.  Thus, it is also serving as catalysts for innovation alongside market growth within this sector throughout Europe.

The hemostats market is projected to grow fastest in the Asia Pacific region. More surgeries, better healthcare facilities and services as well as a thriving medical tourism industry are among the factors attributing to this growth. The number of cosmetic operations has been increasing especially in China, Japan and India. Moreover, it is witnessing swift economic growth which results into higher health care spending coupled with infrastructural developments. There exist huge numbers patients together with increased cases chronic diseases like diabetes thus stimulating demand for these products. Around 94 million people were living with diabetes in South-East Asia region during year 2023. By 2045, it is expected that they will be around 152 million. In addition, significant demand for hemostats can also be attributed from countries that have established themselves as medical tourism destinations such as Thailand, India or Singapore.

Top Players in Global Hemostats Market

• B.Braun Melsungen AG
• Baxter International Inc.
• Becton Dickinson and Co.
• Gelita Medical GmbH
• Hemostatis LLC
• Integra Life Sciences Holding Corp.
• Johnson and Johnson
• Medtronic PLC
• Pfizer Inc.
• Stryker Corp.
• Teleflex Inc.
• Other Prominent Players

Market Segmentation Overview:

By Type

• Topical Hemostats
  • Mechanical Hemostats
    • ORC Based
    • Gelatin Based
    • Collagen Based
• Polysaccharide Based Topical Hemostats
  • Active Hemostats
  • Flowable Hemostats
• Topical Thrombin Based Topical Hemostats
• Others

By Formulation

• Sheet and Pad Hemostats
• Sponge Hemostats
• Powder Hemostats
• Matrix and Gel Hemostats
• Others

By Application

• Orthopedic Surgery
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Reconstructive Surgery
• Gynecological Surgery
• Others

By End User

• Hospitals
• Ambulatory Surgical Centers
• Home Care
• Others

By Distribution Channel

• Online
• Offline
  • Direct
  • Distributor

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America